KDM5A and synovial sarcoma: These effects can be suppressed through KDM5A knockdown, including tyrosine kinase inhibitors (TKI) that target VEGF receptors, such as Pazopanib, the only TKI approved for synovial sarcomas, exerting antitumour effects by inhibiting angiogenesis mediated by VEGF.